Biogen Reports Strong Q4 Earnings and Positive Nusinersen Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Source: Benzinga
Biogen Inc's stock rose by 6.03% as it reached a 52-week high, buoyed by positive news surrounding its recent clinical findings and earnings report.
The company reported a Q4 Non-GAAP EPS of $1.99, exceeding expectations by $0.36, and highlighted the promising results from its DEVOTE study on high-dose nusinersen for spinal muscular atrophy (SMA), which demonstrated significant safety and efficacy. Additionally, the FDA is currently reviewing this treatment, with a decision expected by April 2026, potentially enhancing Biogen's position in the SMA market.
These developments reflect Biogen's resilience in a challenging market, with strong earnings performance and a positive outlook for its innovative therapies, particularly in the SMA treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 198.670
Low
143.00
Averages
204.45
High
246.00
Current: 198.670
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
- Significant Transaction: Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, providing a substantial non-dilutive capital infusion that significantly strengthens its financial position.
- Product Background: The PRV was granted following the FDA's accelerated approval of Avlayah (tividenofusp alfa-eknm) in March 2026 for treating Hunter syndrome, highlighting the drug's market potential and the company's competitiveness in the rare disease sector.
- Advancing Clinical Portfolio: The capital infusion will aid Denali in advancing its broad Transport Vehicle-enabled clinical portfolio focused on lysosomal storage disorders and neurodegenerative diseases, further solidifying its position in the biopharmaceutical industry.
- Collaborations and R&D: Denali collaborates with pharmaceutical giants like Sanofi, Biogen, and Takeda to develop various candidates, and despite the discontinuation of the BIIB122 project with Biogen due to unmet expectations, the company will continue to independently advance other key studies, demonstrating resilience and promising prospects in its R&D efforts.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
U.S. Stock Futures Rise as Investors Eye Four Key Stocks
- Kroger Earnings Volatility: Kroger Co. (KR) dropped 4.89% in premarket trading despite reporting a 2.2% year-over-year revenue increase to $46.1 billion for Q1, as sales excluding fuel and Vitacost only rose 0.5%, indicating competitive pricing pressures that may raise concerns about future performance.
- Paramount Acquisition Approval: Paramount Skydance (PSKY) rose 1.10% in premarket after receiving Chinese regulatory approval for its planned $110 billion acquisition of Warner Bros. Discovery, although it still requires UK and European antitrust clearance, potentially providing a boost for future growth.
- Broadcom Debt Buyback: Broadcom (AVGO) increased 3.07% in premarket following the final results of its cash tender offers to purchase six series of outstanding senior notes, raising the total purchase price from the previously announced $2.5 billion to $3 billion, which may improve liquidity and bolster market confidence.
- Biogen Acquisition Deal: Biogen (BIIB) was up 0.57% in premarket after entering a definitive agreement to acquire private biotech firm RayThera for up to $1 billion, focusing on expanding its pipeline in the high-growth immunology and anti-inflammatory sectors, reflecting a strategic commitment to future growth opportunities.
See More
Biogen Acquires RayThera to Expand Immunology Pipeline
- Acquisition Scale: Biogen has entered into a definitive agreement to acquire RayThera, a private biotechnology firm, in a transaction valued at up to $1 billion, aimed at enhancing Biogen's long-term pipeline in the immunology and anti-inflammatory sectors.
- Payment Structure: The total consideration is heavily back-ended, with an initial cash payment to RayThera shareholders followed predominantly by contingent payments tied to future clinical and regulatory milestones, indicating Biogen's confidence in RayThera's product potential.
- Clinical Development Plans: RayThera's primary asset is scheduled to advance into Phase 1 clinical development in early Q3 2026, with Biogen assuming full operational leadership over global development, manufacturing, and commercialization efforts, further solidifying its market position.
- Regulatory Approval Requirements: The transaction is subject to customary closing conditions and antitrust approvals, projected to officially close in Q3 2026, reflecting Biogen's cautious approach in expanding its product line.
See More
Biogen Acquires RayThera for Up to $1 Billion
- Acquisition Value: Biogen has agreed to acquire RayThera for up to $1 billion, which includes an upfront payment and additional milestone payments tied to clinical and regulatory progress, reflecting the company's commitment to expanding its immunology portfolio.
- Pipeline Development: RayThera's pipeline includes multiple anti-inflammatory assets targeting immune-mediated diseases, with its lead candidate expected to enter Phase 1 trials in Q3 2026, marking the first clinical program to advance under Biogen's ownership and enhancing its pipeline diversity.
- Strategic Integration: Biogen stated that this acquisition strengthens its long-term strategy in immunology, as the early-stage assets will complement its existing portfolio, thereby enhancing its competitive position in the market.
- Global Development Capabilities: RayThera's CEO highlighted Biogen's global development capabilities as a natural fit for advancing their programs into Phase 1 and beyond, which will accelerate clinical progress and enhance market potential for RayThera's assets.
See More
Biogen Acquires RayThera to Enhance Immunology Pipeline
- Acquisition Scale: Biogen announced the acquisition of San Diego-based RayThera for up to $1 billion, which includes upfront payments and milestone payments tied to clinical and regulatory successes, expected to close in Q3 2026, indicating Biogen's ongoing expansion in immunotherapy.
- Pipeline Potential: RayThera focuses on developing small-molecule anti-inflammatory drugs, with its lead candidate set to enter clinical trials in early Q3 2026; Biogen will take full responsibility for further development and global commercialization, enriching its immunology pipeline.
- Strategic Significance: This acquisition marks Biogen's second major deal this year, following the March purchase of Apellis Pharmaceuticals, further solidifying its position in immunology and rare diseases, and is expected to create new revenue growth opportunities.
- Market Reaction: Following the acquisition announcement, Biogen's shares edged down about 0.4% in after-hours trading, although the stock has gained 12% this year, reflecting market recognition of its long-term growth potential.
See More
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
- Significant Transaction: Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, providing a substantial non-dilutive capital infusion that significantly strengthens its financial position.
- Product Background: The PRV was granted following the FDA's accelerated approval of Avlayah (tividenofusp alfa-eknm) in March 2026 for treating Hunter syndrome, highlighting the drug's market potential and the company's competitiveness in the rare disease sector.
- Advancing Clinical Portfolio: The capital infusion will aid Denali in advancing its broad Transport Vehicle-enabled clinical portfolio focused on lysosomal storage disorders and neurodegenerative diseases, further solidifying its position in the biopharmaceutical industry.
- Collaborations and R&D: Denali collaborates with pharmaceutical giants like Sanofi, Biogen, and Takeda to develop various candidates, and despite the discontinuation of the BIIB122 project with Biogen due to unmet expectations, the company will continue to independently advance other key studies, demonstrating resilience and promising prospects in its R&D efforts.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
U.S. Stock Futures Rise as Investors Eye Four Key Stocks
- Kroger Earnings Volatility: Kroger Co. (KR) dropped 4.89% in premarket trading despite reporting a 2.2% year-over-year revenue increase to $46.1 billion for Q1, as sales excluding fuel and Vitacost only rose 0.5%, indicating competitive pricing pressures that may raise concerns about future performance.
- Paramount Acquisition Approval: Paramount Skydance (PSKY) rose 1.10% in premarket after receiving Chinese regulatory approval for its planned $110 billion acquisition of Warner Bros. Discovery, although it still requires UK and European antitrust clearance, potentially providing a boost for future growth.
- Broadcom Debt Buyback: Broadcom (AVGO) increased 3.07% in premarket following the final results of its cash tender offers to purchase six series of outstanding senior notes, raising the total purchase price from the previously announced $2.5 billion to $3 billion, which may improve liquidity and bolster market confidence.
- Biogen Acquisition Deal: Biogen (BIIB) was up 0.57% in premarket after entering a definitive agreement to acquire private biotech firm RayThera for up to $1 billion, focusing on expanding its pipeline in the high-growth immunology and anti-inflammatory sectors, reflecting a strategic commitment to future growth opportunities.
See More
Biogen Acquires RayThera to Expand Immunology Pipeline
- Acquisition Scale: Biogen has entered into a definitive agreement to acquire RayThera, a private biotechnology firm, in a transaction valued at up to $1 billion, aimed at enhancing Biogen's long-term pipeline in the immunology and anti-inflammatory sectors.
- Payment Structure: The total consideration is heavily back-ended, with an initial cash payment to RayThera shareholders followed predominantly by contingent payments tied to future clinical and regulatory milestones, indicating Biogen's confidence in RayThera's product potential.
- Clinical Development Plans: RayThera's primary asset is scheduled to advance into Phase 1 clinical development in early Q3 2026, with Biogen assuming full operational leadership over global development, manufacturing, and commercialization efforts, further solidifying its market position.
- Regulatory Approval Requirements: The transaction is subject to customary closing conditions and antitrust approvals, projected to officially close in Q3 2026, reflecting Biogen's cautious approach in expanding its product line.
See More
Biogen Acquires RayThera for Up to $1 Billion
- Acquisition Value: Biogen has agreed to acquire RayThera for up to $1 billion, which includes an upfront payment and additional milestone payments tied to clinical and regulatory progress, reflecting the company's commitment to expanding its immunology portfolio.
- Pipeline Development: RayThera's pipeline includes multiple anti-inflammatory assets targeting immune-mediated diseases, with its lead candidate expected to enter Phase 1 trials in Q3 2026, marking the first clinical program to advance under Biogen's ownership and enhancing its pipeline diversity.
- Strategic Integration: Biogen stated that this acquisition strengthens its long-term strategy in immunology, as the early-stage assets will complement its existing portfolio, thereby enhancing its competitive position in the market.
- Global Development Capabilities: RayThera's CEO highlighted Biogen's global development capabilities as a natural fit for advancing their programs into Phase 1 and beyond, which will accelerate clinical progress and enhance market potential for RayThera's assets.
See More
Biogen Acquires RayThera to Enhance Immunology Pipeline
- Acquisition Scale: Biogen announced the acquisition of San Diego-based RayThera for up to $1 billion, which includes upfront payments and milestone payments tied to clinical and regulatory successes, expected to close in Q3 2026, indicating Biogen's ongoing expansion in immunotherapy.
- Pipeline Potential: RayThera focuses on developing small-molecule anti-inflammatory drugs, with its lead candidate set to enter clinical trials in early Q3 2026; Biogen will take full responsibility for further development and global commercialization, enriching its immunology pipeline.
- Strategic Significance: This acquisition marks Biogen's second major deal this year, following the March purchase of Apellis Pharmaceuticals, further solidifying its position in immunology and rare diseases, and is expected to create new revenue growth opportunities.
- Market Reaction: Following the acquisition announcement, Biogen's shares edged down about 0.4% in after-hours trading, although the stock has gained 12% this year, reflecting market recognition of its long-term growth potential.
See More
